Abstract
Diabetes mellitus (DM) is an independent cause of cardiomyopathy. It increases the risk of heart failure and mortality, which is not alleviated by intensive glycemic control in clinical trials. Since diabetic cardiomyopathy (DMCM) can not be cured and glycemic control has limited effects on it, novel therapeutic strategies for DMCM are warranted. One of the hallmarks of the DM heart is increased inflammation that contributes to pyroptosis, an inflamamtory cell death mechanism. Pyroptosis results in release of interleukin-1β (IL-1β) and IL-18 inflamamtory cytokines that further increase inflamamtion. Thus, a vicious cycle of inflammation-induced inflammatory cell death continues leading to DMCM. Inflammation also promotes adverse cardiac remodeling leading to DMCM. Thus, the regulation of DM-induced inflammatory cytokines is important. This chapter focuses on the key regulators of inflammatory cytokines in the DM heart and their potential roles as atherapeutic target for DMCM.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Muntner P et al (2018) A comparison of the 2017 American College of Cardiology/American Heart Association blood pressure guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults with diabetes. Diabetes Care 41:2322–2329
Cho NH et al (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281
Nichols GA et al (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27(8):1879–1884
Fox CS (2010) Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med 20(3):90–95
Haffner SM et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234
Nordstrom A et al (2016) Higher prevalence of type 2 diabetes in men than in women is associated with differences in visceral fat mass. J Clin Endocrinol Metab 101(10):3740–3746
Kautzky-Willer A, Harreiter J, Pacini G (2016) Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 37(3):278–316
Ballotari P et al (2017) Sex differences in the effect of type 2 diabetes on major cardiovascular diseases: results from a population-based study in Italy. Int J Endocrinol 2017:6039356
Tripathi BK, Srivastava AK (2006) Diabetes mellitus: complications and therapeutics. Med Sci Monit 12(7):RA130–RA147
Castagno D et al (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162(5):938–948 e2
Sharma A et al (2018) Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol 9:114
Rubler S et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30(6):595–602
Chavali V, Tyagi SC, Mishra PK (2013) Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes 6:151–160
Halade GV, Kain V, Serhan CN (2018) Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. FASEB J 32(7):3717–3729
Pan JA et al (2018) Extracellular volume by cardiac magnetic resonance is associated with biomarkers of inflammation in hypertensive heart disease. J Hypertens 37:65–72
Lee SJ et al (2018) Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction. J Clin Invest 128:5018–5033
Kimura T et al (2018) Tenascin-C accelerates adverse ventricular remodeling after myocardial infarction by modulating macrophage polarization. Cardiovasc Res 115:614–624
Cnop M et al (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2):S97–S107
Wilcox NS et al (2016) Life and death of beta cells in type 1 diabetes: a comprehensive review. J Autoimmun 71:51–58
Pugliese A (2016) Insulitis in the pathogenesis of type 1 diabetes. Pediatr Diabetes 17(Suppl 22):31–36
Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2):98–107
Yu XY et al (2011) Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. PLoS One 6(1):e16239
Younce CW, Wang K, Kolattukudy PE (2010) Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovasc Res 87(4):665–674
Grundy SM (2016) Metabolic syndrome update. Trends Cardiovasc Med 26(4):364–373
Devaraj S, Jialal I (2000) Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 102(2):191–196
Frieler RA, Mortensen RM (2015) Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131(11):1019–1030
Mann DL (2015) Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 116(7):1254–1268
Devaraj S et al (2006) Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55(3):774–779
Volz HC et al (2010) HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105(6):805–820
Yan SF et al (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93(12):1159–1169
Yao D, Brownlee M (2010) Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59(1):249–255
Rojas A et al (2013) The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. Cell Signal 25(3):609–614
Devaraj S et al (2008) Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93(2):578–583
Mano Y et al (2011) Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J 75(7):1717–1727
Pradhan AD et al (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3):327–334
Matsumoto K et al (2001) Serum concentrations of soluble vascular cell adhesion molecule-1 and E-selectin are elevated in insulin-resistant patients with type 2 diabetes. Diabetes Care 24(9):1697–1698
Fasching P, Waldhausl W, Wagner OF (1996) Elevated circulating adhesion molecules in NIDDM--potential mediators in diabetic macroangiopathy. Diabetologia 39(10):1242–1244
Zhang W et al (2015) Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc 4(6):e001993
Hofmann MA et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 42(2):222–232
Baker RG, Hayden MS, Ghosh S (2011) NF-kappaB, inflammation, and metabolic disease. Cell Metab 13(1):11–22
Shah MS, Brownlee M (2016) Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 118(11):1808–1829
Thomas CM et al (2014) Cardiac-specific suppression of NF-kappaB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am J Physiol Heart Circ Physiol 307(7):H1036–H1045
Pan Y et al (2014) Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 63(10):3497–3511
Kaneto H et al (2004) Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabet Stud 1(4):165–174
Li G et al (2007) Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology 148(7):3356–3363
Donath MY et al (2003) Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med (Berl) 81(8):455–470
Frati G et al (2017) An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res 113(4):378–388
Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98(5):596–605
Nishida K, Otsu K (2017) Inflammation and metabolic cardiomyopathy. Cardiovasc Res 113(4):389–398
Westermann D et al (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56(3):641–646
Luo B et al (2017) NLRP3 inflammasome as a molecular marker in diabetic cardiomyopathy. Front Physiol 8:519
Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119(1):159–176
Monnerat G et al (2016) Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat Commun 7:13344
Mishra PK et al (2017) Diabetic cardiomyopathy: an immunometabolic perspective. Front Endocrinol (Lausanne) 8:72
Mishra PK et al (2009) MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 13(4):778–789
Tyagi AC, Sen U, Mishra PK (2011) Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases. Curr Diabetes Rev 7(6):367–376
Zhang Y et al (2017) Emerging roles for microRNAs in diabetic microvascular disease: novel targets for therapy. Endocr Rev 38(2):145–168
Shantikumar S, Caporali A, Emanueli C (2012) Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 93(4):583–593
Liang YZ et al (2018) Identification of stress-related microRNA biomarkers in type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes
Zhang Y et al (2016) Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFbeta1 and miR-29 pathways. Sci Rep 6:23010
Brennan E et al (2017) Protective effect of let-7 miRNA family in regulating inflammation in diabetes-associated atherosclerosis. Diabetes 66(8):2266–2277
Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115(5):1111–1119
Williams LJ, Nye BG, Wende AR (2017) Diabetes-related cardiac dysfunction. Endocrinol Metab (Seoul) 32(2):171–179
Mao XM et al (2009) Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 25(5):435–441
Paneni F, Luscher TF (2017) Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Med 130(6S):S18–S29
Gundewar S et al (2009) Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104(3):403–411
Xie Z et al (2011) Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60(6):1770–1778
Caballero AE et al (2004) The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 89(8):3943–3948
Nesti L, Natali A (2017) Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr Metab Cardiovasc Dis 27(8):657–669
Pollack RM et al (2016) Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39(Suppl 2):S244–S252
Shekelle PG et al (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41(9):1529–1538
Zaman AK et al (2004) Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 37(2):525–535
Sahebkar A et al (2016) Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. Br J Clin Pharmacol 81(5):807–818
Palazzuoli A et al (2018) Clinical impact of oral antidiabetic medications in heart failure patients. Heart Fail Rev 23(3):325–335
Kumar R, Kerins DM, Walther T (2016) Cardiovascular safety of anti-diabetic drugs. Eur Heart J Cardiovasc Pharmacother 2(1):32–43
Reddy MA et al (2014) Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. Diabetes 63(12):4249–4261
Assmann TS et al (2017) MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. Endocr Connect 6(8):773–790
Ventriglia G et al (2015) MicroRNAs: novel players in the dialogue between pancreatic islets and immune system in autoimmune diabetes. Biomed Res Int 2015:749734
Sebastiani G et al (2015) MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol 52(3):523–530
Lew JK et al (2017) Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc Diabetol 16(1):10
Nandi SS et al (2016) Lack of miR-133a decreases contractility of diabetic hearts: a role for novel cross talk between tyrosine aminotransferase and tyrosine hydroxylase. Diabetes 65(10):3075–3090
Guo R, Nair S (2017) Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Biochim Biophys Acta Mol basis Dis 1863(8):2070–2077
Moura J, Borsheim E, Carvalho E (2014) The role of microRNAs in diabetic complications-special emphasis on wound healing. Genes (Basel) 5(4):926–956
Younk LM, Lamos EM, Davis SN (2016) Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf 15(9):1239–1257
Brown NJ (2012) Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens 6(3):163–168
Rosano GM, Vitale C, Seferovic P (2017) Heart failure in patients with diabetes mellitus. Card Fail Rev 3(1):52–55
Standl E, Schnell O, McGuire DK (2016) Heart failure considerations of Antihyperglycemic medications for type 2 diabetes. Circ Res 118(11):1830–1843
Zheng SL et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319(15):1580–1591
El Masri D, Ghosh S, Jaber LA (2018) Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 137:83–92
Okopień B et al (2005) Monocyte suppressing action of fenofibrate. Pharmacol Rep 57(3):367–372
Sakoda K et al (2006) Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 85(6):520–523
Henrich D et al (2007) High dosage of simvastatin reduces TNF-α-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1β in vitro. J Surg Res 142(1):13–19
Tsutamoto T et al (2000) Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35(3):714–721
Trevelyan J et al (2004) Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol 94(5):564–569
Andrzejczak D, Górska D, Czarnecka EJPrP (2007) Influence of enalapril, quinapril and losartan on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1 beta, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep 59(4):437–446
Polyzos SA, Kountouras J, Zavos C (2010) Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatol Res 40(4):446–447
Luan Z et al (2003) Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23(5):769–775
Rosenson RS, Tangney CC, Casey LC (1999) Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353(9157):983–984
Sun Y et al (2013) MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines. Cell Res 23(11):1270
Sonkoly E, Ståhle M, Pivarcsi A (2008) MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. In: Seminars in cancer biology. Elsevier, London
Boesch-Saadatmandi C et al (2011) Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155. J Nutr Biochem 22(3):293–299
Huang L et al (2016) MicroRNA-223 promotes tumor progression in lung cancer A549 cells via activation of the NF-κB signaling pathway. Oncol Res 24(6):405–413
Curtale G et al (2013) Negative regulation of toll-like receptor 4 signaling by IL-10–dependent microRNA-146b. Proc Natl Acad Sci U S A 110(28):11499–11504
Puthanveetil P et al (2015) Long non-coding RNA MALAT 1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med 19(6):1418–1425
Atianand MK et al (2016) A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell 165(7):1672–1685
Rapicavoli NA et al (2013) A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics. elife 2:e00762
Zhao G et al (2016) The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-κB. FEBS Lett 590(17):2884–2895
Fitzgerald KA, Caffrey DR (2014) Long noncoding RNAs in innate and adaptive immunity. Curr Opin Immunol 26:140–146
Du M et al (2017) The LPS-inducible lncRNA Mirt2 is a negative regulator of inflammation. Nat Commun 8(1):2049
Cui H et al (2014) The human long noncoding RNA lnc-IL 7 R regulates the inflammatory response. Eur J Immunol 44(7):2085–2095
Acknowledgements
This work is supported, in parts, by the National Institutes of Health grants HL-113281 and HL-116205 to Paras K. Mishra.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Yadav, S.K., Kambis, T.N., Mishra, P.K. (2019). Regulating Inflammatory Cytokines in the Diabetic Heart. In: Chakraborti, S., Dhalla, N., Ganguly, N., Dikshit, M. (eds) Oxidative Stress in Heart Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-13-8273-4_19
Download citation
DOI: https://doi.org/10.1007/978-981-13-8273-4_19
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8272-7
Online ISBN: 978-981-13-8273-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)